Alzheimer’s /Dementia Global Landscape 2026

Alzheimer’s / Dementia — 2026 Global Landscape

A World Economic Forum–Style Policy Brief

Therapeutics | Biomarkers | Diagnostics | System Convergence

Author: KJ Lavan

https://www.linkedin.com/in/kj-lavan-1739ab226

⸻

Executive Summary

Alzheimer’s disease is entering a systems inflection point. 

After decades of scientific uncertainty, the field is transitioning from proof-of-concept breakthroughs to implementation architecture where who gets treated, when, and at what cost becomes the defining challenge.¹ ²

Three forces are converging:

• Therapeutics are moving toward precision, earlier intervention, and combinatorial approaches⁴

• Biomarkers are becoming the clinical and economic gatekeepers⁵ ⁶

• Diagnostics are evolving into scalable, multi-layer access systems³

This convergence is reshaping Alzheimer’s from a late-stage clinical condition into a longitudinal, biomarker-defined disease continuum with profound implications for health systems, workforce capacity, and global economic productivity.¹ ⁷ ⁸

⸻

I. Therapeutics

Shift: From Proof-of-Concept → Precision, Prevention, and Scalability

The approval of disease-modifying therapies such as Leqembi (Eisai / Biogen) and Kisunla (Eli Lilly) marks a transition from validation of the amyloid hypothesis to optimization and stratification.⁴

Key Trends & Global Actors

1. Anti-amyloid optimization era

• Earlier intervention, reduced ARIA risk, subcutaneous delivery⁴

• Actors: Eisai, Biogen, Eli Lilly

2. Next-generation delivery platforms

• Blood-brain barrier (BBB) penetration technologies improving CNS drug delivery

• Example: Roche (Brainshuttle / trontinemab)

3. Beyond amyloid: tau & oligomers

• Shift toward toxic species and propagation pathways

• Actors: Acumen Pharmaceuticals, Prothena + Bristol Myers Squibb

4. Genotype-driven precision medicine

• APOE4-targeted therapies emerging

• Actor: Alzheon

5. Oral & scalable therapeutics

• Movement beyond infusion-only delivery models

6. Combination therapy (next wave)

• Amyloid + tau + neuroinflammation convergence across pipelines

Strategic Signal:

Therapeutics are no longer defined by efficacy alone, but by timing, patient stratification, delivery scalability, and combinatorial integration.⁴

⸻

II. Biomarkers

Shift: From Research Tools → Clinical & Economic Gatekeepers

Blood-based biomarkers are transforming Alzheimer’s into a measurable, stratifiable condition, fundamentally reshaping clinical pathways, reimbursement, and access.³ ⁵ ⁶

Key Trends & Global Actors

1. p-tau217 dominance

• Most predictive plasma biomarker emerging in clinical research⁵

• Actors: ALZpath, Quanterix

2. Multi-analyte panels

• Integration of pTau + Aβ + GFAP + NfL + ApoE

• Actors: Quanterix, Roche Diagnostics

3. Platform standardization

• Automation and global lab scalability

• Actors: Siemens Healthineers, Fujirebio

4. Biomarkers as treatment gateways

• Trial recruitment, therapy eligibility, longitudinal monitoring³

• Actor: C2N Diagnostics

5. Decentralization of testing

• Expansion into mainstream clinical environments

Strategic Signal:

Biomarkers are becoming the control layer of Alzheimer’s care—determining access, eligibility, pricing, and system burden.³ ⁵

⸻

III. Diagnostics

Shift: From Specialist Bottlenecks → Scalable, Blood-First Systems

Diagnostics are transitioning from high-cost, specialist-dependent pathways to tiered, scalable, AI-enabled ecosystems.³

Key Trends & Global Actors

1. Blood-based diagnostics (inflection point)

• Transition from PET-first → blood-first models³

• Actors: Fujirebio, Roche

2. Tiered diagnostic pathways

• “Rule-out → confirm → treat”

• Actors: C2N Diagnostics, Quest Diagnostics

3. AI-enabled imaging

• PET/MRI with automated quantification

• Actor: Siemens Healthineers

4. Digital-first screening layer

• Remote cognitive tools and AI-enabled assessments

5. Longitudinal monitoring systems

• Continuous vs episodic diagnosis

• Integration of digital + biomarker ecosystems³

Strategic Signal:

Diagnostics are evolving into a multi-layer infrastructure:

Digital front door → Blood-based triage → Imaging confirmation → Treatment pathway³

⸻

IV. System Convergence

The Emergence of a New Alzheimer’s Architecture

Across therapeutics, biomarkers, and diagnostics, a unified system is forming:

Alzheimer’s is becoming:

• Blood-test defined⁵

• Biomarker-gated³

• Earlier-stage treated⁴

• Digitally monitored³

• Economically stratified⁷

This represents a transition from episodic care → continuous disease management infrastructure.⁷ ⁸

⸻

V. Policy Implications (WEF Lens)

1. Health System Readiness Gap

• Workforce shortages in neurology and geriatrics¹

• Limited infusion and monitoring infrastructure¹

• Uneven access to biomarker testing³

2. Economic Stratification Risk

• Biomarker-gated therapies may create tiered access systems⁷

• High-cost biologics risk widening inequities¹

3. Regulatory Transformation

• Shift from symptom-based → biological diagnosis⁴

• Need for harmonized global regulatory frameworks¹

4. Data & Infrastructure Imperative

Integration of:

• Biomarker data

• Imaging

• Digital monitoring

Requires interoperable, secure, longitudinal systems⁷ ⁸

⸻

VI. Strategic Framework: The Alzheimer’s Stack
Layer	Function	Strategic Role
Therapeutics	Intervention	Slows/modifies disease
Biomarkers	Decision Layer	Determines eligibility & timing
Diagnostics	Access Layer	Enables scalable system entry

Winning Strategy:

Organizations that integrate all three layers into a coherent, scalable care pathway—not standalone innovation—will define the future of Alzheimer’s care.³ ⁷

⸻

Conclusion

Alzheimer’s is no longer just a scientific frontier.

It is evolving into an economic and systems design challenge.⁷

The next decade will not be defined by a single breakthrough drug, but by:

The ability to operationalize a globally scalable, biomarker-driven, digitally enabled brain health infrastructure.⁷ ⁸

⸻

References

1. Alzheimer’s Association. 2025 Alzheimer’s Disease Facts and Figures.

2. Alzheimer’s Disease International. World Alzheimer Report.

3. Alzheimer’s Drug Discovery Foundation. Diagnostics Accelerator Reports (DxA 3.0).

4. U.S. Food and Drug Administration. Regulatory decisions on lecanemab and donanemab (2023–2025).

5. Palmqvist S. et al. (2020–2024). Plasma p-tau217 as a biomarker for Alzheimer’s disease.

6. Karikari T.K. et al. (2020–2023). Blood biomarkers for Alzheimer’s pathology.

7. World Economic Forum. The Human Advantage: Stronger Brains in the Age of AI (2026).

8. McKinsey Health Institute. Brain capital and cognitive resilience reports (2024–2026).

Author: KJ Lavan

https://www.linkedin.com/in/kj-lavan-1739ab226